Wells Fargo & Company MN Has $1.09 Million Holdings in InMode Ltd. (NASDAQ:INMD)

Wells Fargo & Company MN lifted its position in shares of InMode Ltd. (NASDAQ:INMD) by 8.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 65,333 shares of the healthcare company’s stock after acquiring an additional 5,068 shares during the quarter. Wells Fargo & Company MN owned approximately 0.09% of InMode worth $1,091,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in INMD. River Road Asset Management LLC bought a new stake in shares of InMode during the fourth quarter worth $8,572,000. Norges Bank bought a new position in shares of InMode during the 4th quarter worth approximately $2,943,000. Seizert Capital Partners LLC raised its holdings in shares of InMode by 105.2% in the fourth quarter. Seizert Capital Partners LLC now owns 250,627 shares of the healthcare company’s stock valued at $4,185,000 after purchasing an additional 128,483 shares during the last quarter. Barclays PLC lifted its position in shares of InMode by 113.5% in the third quarter. Barclays PLC now owns 169,630 shares of the healthcare company’s stock worth $2,876,000 after purchasing an additional 90,173 shares in the last quarter. Finally, Trexquant Investment LP boosted its holdings in InMode by 105.0% during the fourth quarter. Trexquant Investment LP now owns 170,486 shares of the healthcare company’s stock worth $2,847,000 after purchasing an additional 87,305 shares during the last quarter. 68.04% of the stock is currently owned by institutional investors and hedge funds.

InMode Trading Up 1.1 %

Shares of NASDAQ INMD opened at $14.42 on Wednesday. InMode Ltd. has a 12 month low of $13.68 and a 12 month high of $19.85. The stock has a 50 day moving average of $17.16 and a 200-day moving average of $17.61. The company has a market capitalization of $1.00 billion, a P/E ratio of 6.14 and a beta of 1.96.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Jefferies Financial Group cut their price target on shares of InMode from $16.00 to $15.00 and set a “hold” rating on the stock in a research report on Monday, April 14th. Barclays increased their price target on InMode from $26.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, February 5th. Robert W. Baird lowered InMode from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $22.00 to $16.00 in a research report on Monday. Canaccord Genuity Group cut their price objective on InMode from $17.00 to $15.00 and set a “hold” rating for the company in a report on Tuesday. Finally, UBS Group lowered their target price on shares of InMode from $19.00 to $16.25 and set a “neutral” rating on the stock in a report on Tuesday. Seven analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $19.38.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.